MCL-1 degradation mediated by JNK activation via MEKK1/TAK1-MKK4 contributes to anticancer activity of new tubulin inhibitor MT189.

Wang W, Wang YQ, Meng T, Yi JM, Huan XJ, Ma LP, Tong LJ, Chen Y, Ding J, Shen JK, Miao ZH
Mol Cancer Ther. 2014 Jun;13(6):1480-91. doi: 10.1158/1535-7163.MCT-13-0629. Epub 2014 Mar 31. PubMed Article

Plasmids from Article

No plasmids are currently publicly available from Addgene for this article.